Lexaria Bioscience Corp. (LEXX)

Market Cap	38.92M
Revenue (ttm)	464,278
Net Income (ttm)	-5.80M
Shares Out	17.45M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,586
Open	2.220
Previous Close	2.210
Day's Range	2.150 - 2.235
52-Week Range	1.200 - 6.850
Beta	1.08
Analysts	Strong Buy
Price Target	11.00 (+393.27%)
Earnings Date	Jan 10, 2025

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules, including...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX
• Website: https://lexariabioscience.com

Financial Performance

In 2024, Lexaria Bioscience's revenue was $464,278, an increase of 105.24% compared to the previous year's $226,208. Losses were -$5.80 million, -13.05% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for LEXX stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 393.27% from the latest price.

Price Target

$11.0

(393.27% upside)

Analyst Consensus: Strong Buy